Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.63 |
| ▸ | CNR2 | P34972 | 1/20 | 0.54 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | AXL | P30530 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 0.48 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.47 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.46 |
| ▸ | CDK2 | P24941 | 4/20 | 0.46 |
| ▸ | KIF20A | O95235 | 1/20 | 0.46 |
| ▸ | CLK1 | P49759 | 1/20 | 0.46 |
| ▸ | CLK2 | P49760 | 1/20 | 0.46 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.46 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29443820 | 0.87 | MAP2K1 (0.67) | MAP2K1CNR2ADORA2AKMT2AAXL | |
| SCHEMBL3608096 | 0.87 | MAP2K1 (0.67) | MAP2K1CNR2ADORA2AKMT2AAXL | |
| SCHEMBL1474975 | 0.85 | MAP2K1 (0.65) | MAP2K1CNR2ADORA2AKMT2AAXL | |
| Hydrochloric Acid SCHEMBL23727982 | 0.85 | MAP2K1 (0.65) | MAP2K1CNR2ADORA2AKMT2AAXL | |
| SCHEMBL13325426 | 0.84 | MAP2K1 (0.68) | MAP2K1CNR2ADORA2AKMT2AAXL | |
| Potassium Ion SCHEMBL29688228 | 0.84 | MAP2K1 (0.63) | MAP2K1CNR2ADORA2AKMT2AAXL | |
| Hydrochloric Acid SCHEMBL3595977 | 0.84 | MAP2K1 (0.63) | MAP2K1CNR2ADORA2AKMT2AAXL | |
| Potassium Ion SCHEMBL2688784 | 0.84 | MAP2K1 (0.63) | MAP2K1CNR2ADORA2AKMT2AAXL | |
| SCHEMBL1867330 | 0.84 | MAP2K1 (0.63) | MAP2K1CNR2ADORA2AKMT2AAXL | |
| SCHEMBL985214 | 0.83 | MAP2K1 (0.71) | MAP2K1CNR2ADORA2AKMT2AAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7169787-B2 | 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same | ELBION AG (DE) | 2007-01-30 | — | — | US | claimed |
| EP-1330455-B1 | NOVEL 7-AZAINDOLES, USE THEREOF AS PHOSPHODIESTERASE 4 INHIBITORS AND METHOD FOR PRODUCING THE SAME | ELBION AG (DE) | 2005-08-03 | — | — | EP | claimed |
| US-20040106641-A1 | Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same | BIOTIE THERAPIES GMBH (DE) | 2004-06-03 | — | — | US | claimed |
| EP-1330455-A1 | NOVEL 7-AZAINDOLES, USE THEREOF AS PHOSPHODIESTERASE 4 INHIBITORS AND METHOD FOR PRODUCING THE SAME | Elbion AG (DE) | 2003-07-30 | — | — | EP | claimed |
| WO-2002034747-A1 | NOVEL 7-AZAINDOLES, USE THEREOF AS PHOSPHODIESTERASE 4 INHIBITORS AND METHOD FOR PRODUCING THE SAME | ELBION AG (DE) | 2002-05-02 | — | — | WO | claimed |
| US-7683074-B2 | 7-azaindoles, their use as inhibitors of phosphodiesterase 4, and a method for synthesizing them | BIOTIE THERAPIES GMBH (DE) | 2010-03-23 | — | — | US | disclosed |
| US-7419987-B2 | 7-azaindoles, their use as inhibitors of phosphodiesterase 4, and a method for synthesizing them | ELBION AG (DE) | 2008-09-02 | — | — | US | disclosed |
| US-20080207680-A1 | 7-Azaindoles, their use as inhibitors of phosphodiesterase 4, and a method for synthesizing them | BIOTIE THERAPIES GMBH (DE) | 2008-08-28 | — | — | US | disclosed |
| US-7169787-B2 | 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same | ELBION AG (DE) | 2007-01-30 | — | — | US | disclosed |
| US-20060258700-A1 | 7-azaindoles, their use as inhibitors of phosphodiesterase 4, and a method for synthesizing them | BIOTIE THERAPIES GMBH (DE) | 2006-11-16 | — | — | US | disclosed |
| EP-1330455-B1 | NOVEL 7-AZAINDOLES, USE THEREOF AS PHOSPHODIESTERASE 4 INHIBITORS AND METHOD FOR PRODUCING THE SAME | ELBION AG (DE) | 2005-08-03 | — | — | EP | disclosed |
| US-20040106641-A1 | Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same | BIOTIE THERAPIES GMBH (DE) | 2004-06-03 | — | — | US | disclosed |
| EP-1330455-A1 | NOVEL 7-AZAINDOLES, USE THEREOF AS PHOSPHODIESTERASE 4 INHIBITORS AND METHOD FOR PRODUCING THE SAME | Elbion AG (DE) | 2003-07-30 | — | — | EP | disclosed |
| WO-2002034747-A1 | NOVEL 7-AZAINDOLES, USE THEREOF AS PHOSPHODIESTERASE 4 INHIBITORS AND METHOD FOR PRODUCING THE SAME | ELBION AG (DE) | 2002-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106641-A1 | Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same | PDE4A, PDE4B, PDE4C | MAP2K1 2469/4885CNR2 2555/4885ADORA2A 518/4885 |
| US-20060258700-A1 | 7-azaindoles, their use as inhibitors of phosphodiesterase 4, and a method for synthesizing them | PDE4A, PDE4B, PDE3A | MAP2K1 2712/4885CNR2 3086/4885ADORA2A 541/4885 |
| US-20080207680-A1 | 7-Azaindoles, their use as inhibitors of phosphodiesterase 4, and a method for synthesizing them | PDE4A, PDE4B, PDE7A | MAP2K1 2198/4885CNR2 2944/4885ADORA2A 471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.